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Potential mechanisms of marked hyperoxaluria not due to greater than 50% of cases [2–4]. Idiopathic hypercal-
primary hyperoxaluria I or II. ciuria is identified in up to one half of patients with a
Background. Hyperoxaluria may be idiopathic, secondary, recognized metabolic risk factor, and the majority ofor due to primary hyperoxaluria (PH). Hepatic alanine:glyoxy-
stones are comprised of calcium oxalate or calcium phos-late aminotransferase (AGT) or glyoxylate/hydroxypyruvate
phate [2–5]. Hyperoxaluria in pediatric stone disease isreductase (GR/HPR) deficiency causes PHI or PHII, respec-
tively. Hepatic glycolate oxidase (GO) is a candidate enzyme less frequent, observed in 1 to 20% of children who
for a third form of inherited hyperoxaluria. undergo metabolic evaluation for urolithiasis [3, 4, 6],
Methods. Six children were identified with marked hyper- and may be primary, secondary or idiopathic. Markedoxaluria, urolithiasis, and normal hepatic AGT (N  5) and
and persistent hyperoxaluria, exceeding 1.0 to 1.5 mmol/GR/HPR (N  4). HPR was below normal and GR not mea-
1.73 m2/24 h, most often heralds one of the inherited hy-sured in one. Of an affected sibling pair, only one underwent
biopsy. GO mutation screening was performed, and dietary peroxalurias due to hepatic enzyme deficiency of alanine:
oxalate (Dietox), enteric oxalate absorption (EOA) measured glyoxylate aminotransferase (AGT) in type I primary
using [13C2] oxalate, renal clearance (GFR), fractional oxalate hyperoxaluria (PHI) or glyoxylate/hydroxypyruvate re-excretion (FEox) in the children, and urine oxalate in first-
ductase (GR/HPR) in type II primary hyperoxaluriadegree relatives (FDR) to understand the etiology of the hyper-
(PHII). Glycolate oxidase (GO), another hepatic en-oxaluria.
Results. Mean presenting age was 19.2 months and urine zyme contributing to glyoxylate synthesis, a key precur-
oxalate 1.3  0.5 mmol/1.73 m2/24 h (mean  SD). Two GO sor step of endogenous oxalate, is a candidate enzyme for
sequence changes (T754C, IVS3 – 49 CG) were detected a third form of inherited hyperoxaluria (Fig. 1). Williams,which were not linked to the hyperoxaluria. Dietox was 42 
Cregeen and Rumsby recently isolated and expressed31 mg/day. EOA was 9.4  3.6%, compared with 7.6  1.2%
the cDNA for human liver GO [7].in age-matched controls (P  0.33). GFR was 90  19 mL/
min/1.73 m2 and FEox 4.2  1.4. Aside from the two brothers, Enteric hyperoxaluria is typically evident from a clini-
hyperoxaluria was not found in FDR. cal history or findings of intestinal malabsorption, is mod-
Conclusions. These patients illustrate a novel form of hyper-
erate to marked, and varies widely with dietary changesoxaluria and urolithiasis, without excess Dietox, enteric hyper-
(0.7 to1.0 mmol/1.73 m2/24 h) [8]. Other secondary formsabsorption, or hepatic AGT, GR/HPR deficiency. Alterations
in pathways of oxalate synthesis, in liver or kidney, or in renal of hyperoxaluria include dietary oxalate excess and in-
tubular oxalate handling are possible explanations. The af- creased gastrointestinal absorption not due to gastroin-
fected sibling pair suggests an inherited basis. testinal disease or resection. Recent evidence suggests a
role for oxalate-degrading gut flora in the latter form of
hyperoxaluria [9]. Pyridoxine is an essential cofactor of
Childhood urolithiasis in the United States is esti- AGT and its deficiency is a theoretical consideration—
mated to account for between 1 in 1000 to 1 in 7600 hos- though to date unproven—as a clinical cause of urolithi-
pital admissions [1]. Metabolic risk factors account for asis in humans. Idiopathic hyperoxaluria, a diagnosis of
exclusion, is generally mild (0.7 mmol/1.73 m2/24 h).
Our current study describes six children, from five
Key words: enteric oxalate absorption, calcium oxalate urolithiasis,
unrelated families, with moderate to marked hyperoxal-alanine:glyoxylate aminotransferase, stone formation, kidney stones,
urolithiasis. uria and calcium oxalate urolithiasis in the absence of any
known primary or secondary cause. A novel enzymaticReceived for publication January 11, 2002
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the adult normal reference range is applicable in children
[13]. All urine samples for oxalate determination were
acidified to pH 2 with hydrochloric acid. Urine gly-
colate and l-glycerate were measured by gas chromatog-
raphy on two-hour fasting urine specimens [14]. In our
laboratory, the normal reference ranges are 70 g/mg
creatinine and 19 g/mg creatinine, respectively.
Measurements of creatinine, phosphorous, calcium,
and uric acid in serum and urine were by standard labora-
tory methods. Measurement of urine citrate was by the
colorimetric method of Natelson, Pincus and Lugovoy [15].
The renal threshold phosphate concentration (TmPO4/
GFR) was derived from the nomogram of Walton and
Bijvoet using the plasma phosphate concentration and
Fig. 1. Schematic representation of the proposed pathways of glyoxy- the measured fractional tubular reabsorption of phos-
late metabolism in the human liver cell. Abbreviations are: AGT, phate (TRP) [16]. Age-appropriate pediatric reference
alanine:glyoxylate aminotransferase; DAO, D-amino acid oxidase;
ranges for TmPO4/GFR and TRP were obtained fromD-GDH, D-glycerate dehydrogenase; GO, glycolate oxidase; GR, gly-
oxylate reductase; HPR, hydroxypyruvate reductase; LDH, lactate de- published reports [17, 18]. Fasting urine specimens were
hydrogenase; plp, pyridoxal phosphate, an essential cofactor of AGT. screened for organic acids by capillary gas chromatogra-
phy mass spectrometry [19] and for amino acids by ion
exchange chromatography [20].
Renal function was measured by two-hour clearanceMETHODS
of non-radiolabeled iothalamate using capillary electro-
From 1984 to 2000, six children were identified from phoresis [21]. Fractional oxalate excretion (FEox) was
five unrelated families who had persistent moderate to calculated from the renal clearance of oxalate and the
marked hyperoxaluria (greater than 0.9 mmol/1.73 simultaneous renal clearance of creatinine (CCr). Values
m2/24 h) and calcium oxalate urolithiasis. Percutaneous less than unity were considered to represent net renal
hepatic biopsies were obtained in five of the children. tubular oxalate reabsorption and values exceeding unity
In the family with two affected siblings, only one child to suggest net renal tubular oxalate secretion [22]. The
underwent biopsy. Hepatic enzyme analyses for AGT fractional excretion of uric acid (FEUA) was calculated
and GR/HPR were performed in the laboratory of Dr. from simultaneous fasting blood and urine samples of
Gill Rumsby using previously published methods uric acid and creatinine. The FEUA in healthy children
[10, 11]. decreases as they get older [23–25].
The children were evaluated for secondary causes of High-pressure liquid chromatography (HPLC) and a
hyperoxaluria, including assessment of dietary oxalate, radioreceptor assay were used to measure 25-hydroxy
measurement of enteric oxalate absorption using [13C2] and 1,25-dihydroxy vitamin D levels [26, 27]. In children,
oxalate, serum levels of pyridoxine and its metabolites, the circulating concentrations of these vitamin D metab-
plasma oxalate concentrations, glomerular filtration rate olites vary with age [28]. Blood levels of pyridoxine and
(GFR), and calculation of renal fractional oxalate excre- its metabolites were also measured using HPLC [29].
tion. Six age-matched healthy children participated in Levels of parathyroid hormone were determined by the
the [13C2] oxalate absorption study. immunochemiluminometric parathyroid hormone assay
First-degree family members completed a 24-hour urine (ICMA-PTH) [30]. The normal reference range in our
collection for calcium, oxalate, and creatinine. Blood laboratory is 1.0 to 5.2 pmol/L. Stool samples were ana-
samples for DNA analyses were obtained from the six lyzed for fat using the gravimetric method of Van de
probands and their first-degree relatives for mutation Kamer et al [31] and published pediatric reference ranges
screening of the GO gene. The study protocol was ap- [32]. Stone recovery was by urologic procedure and stone
proved by the Mayo Clinic Institutional Review Board analysis was by infrared spectroscopy.
(IRB). Dye-binding assays were used for urine protein quanti-
fication, Coomassie Blue for 24-hour collections, and
Methods for laboratory evaluation Pyrogallol Red for random samples [33]. Urine osmolal-
Plasma and urine oxalate were measured by the immo- ity measurement for calculation of urine protein/osmo-
bilized oxidase method [12]. Our normal reference range lality ratios (mg/L/mOsm/kg) was by freezing point de-
for plasma oxalate is 0.4 to 3.0 mol/L and for 24-hour pression and random urine glucose concentration by the
urine oxalate 0.11 to 0.46 mmol. When measured values glucose oxidase method (normal 25 mg/dL). The nor-
mal value for a random urine protein/osmolality ratio isfor urine oxalate are corrected for body surface area,
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Table 1. Eight exons of the GO gene
Exon/ Product Exon/ Product
primer Sequence (5 to 3) length bp primer Sequence (5 to 3) length bp
1F GTAGAAAGCAATACATTAAAA 5F AAGCTGCCTGTTAAGTT
1R TTTGTGTAATTTTAAAACATG 249 5R GAGGAGGAAGACATAGAGATA 226
2F CTGAAACTCTAAAGCCTTTTA 6F GAGTCACATTATTGAACTTT
2R GGTCGATAAACGTTAGCCTCC 247 6R TTGTTTTACTGTCAAGTTGTC 243
3F GGCCCATCTTGATCATC 7F AAACAAATGAATAAAACAAGT
3R TTCCCAGTCAAGATCCCTTTC 342 7R CCAAGGACCTTGACTTAAA 200
4F AATGAGCAGTGAACAGCCAA 8F GGGAAAACGATTACCTG
4R CAGAGAATTGAGAGTTGGAATGTC 426 8R TCTTTGTCAAGTAATACATGC 200
6.5F AATTGTGGAGGCTGTGGAAG 6.5R CCCACACTCTTCCCTTTCAA 424
0.12 in adults [34] and the 95th percentile for normal, urine volumes for each of the three two-hour periods.
non-proteinuric children is 0.23 [35]. The percent recovery of [13C2] oxalic acid in the six hours
of urine collection is expressed as a fraction of the total
Methods for measurement of enteric ingested dose (mg) of [13C2] oxalic acid.
oxalate absorption Parents recorded a 72-hour food diary for each child.
Enteric oxalate absorption was measured in the Gen- A research dietitian performed all food analyses. Com-
eral Clinical Research Center using a labeled stable iso- puter-based assessments of dietary calcium, sodium and
tope of oxalate ([13C2] oxalate) as described by Liebman protein were made using the 4.1 version of the Nutrition-
and Chai [36]. Except for water, patients and the six age- ist IV First Databank program. Published data were used
matched healthy control children were asked to remain to estimate the oxalate content of food [37, 38].
fasting after midnight. On the morning of the study, a
baseline two-hour urine collection was completed. Pa- Methods for molecular analysis of human liver
tients then ingested a small amount of grape-flavored glycolate oxidase
jello, containing 20 mg/1.73 m2 of [13C2] oxalic acid and Genomic DNA was isolated from blood using stan-
100 mg/1.73 m2 of [12C2] oxalic acid. No other food was dard methods. Control DNA samples were obtained from
ingested. Three sequential two-hour urine collections the University College London Hospitals Primary Hy-
followed for the next six hours, during which time only peroxaluria Service. The coding region of the GO gene
distilled water was taken orally. was ascertained by comparison of genomic (Genbank
Oxalic acid was isolated from 200 L of acidified urine accession number AL021879) and cDNA (Genbank ac-
by applying the sample over a column containing a 1 mL cession number AF244134) sequences. Primer pairs in-
bed volume of Dowex AG 50W-X8 cation exchange resin.
clusive of intron-exon boundaries were designed for each
The column was then rinsed with 2 1 mL 0.1 N HCl and
of the eight exons comprising the GO gene. The selectedthe eluant collected and combined. After drying in a Sa-
oligonucleotide primer pairs for each exon, with theirvant centrifugal evaporator, the sample was derivatized
expected amplicon lengths are in Table 1.with N-methyl-N-(t-butyldimethylsilyl)-trifluoroacet-
The optimized annealing temperatures (Ta) for theamide	 1% t-butyl-dimethylchlorosilane (MTBSTFA	
corresponding primer pairs of exons 1 to 8 were 50, 52,1% t-BDMCS) in acetonitrile at 70
C for 30 minutes. The
56, 52, 56, 54, 54 and 58
C, respectively. With the excep-oxalate derivative was analyzed on a Hewlett Packard
tion of exon 1, which required 2.0 mmol/L magnesium5989B Gas Chromatograph Mass Spectrometer (Palo
for amplification, 1.5 mmol/L magnesium was used forAlto, CA, USA) under electron ionization conditions
all other exons. Amplification consisted of an initial de-using a DB5MS 30 m 0.25 mm I.D. 0.5 m capillary
naturation step (94
C) for two minutes, followed by 30column (J & W Scientific, a division of Agilent Technolo-
cycles of annealing (Ta), extension (72
C), and denatur-gies, Palo Alto, CA, USA). Fragment ions at m/z 261
ation (94
C), each for 30 seconds, and a final extensionand m/z 263 were monitored to determine the [13C2] oxa-
for five minutes. A second set of primers (6.5F and 6.5R,lic acid enrichment. Concentration of oxalate in the urine
Ta of 60
C) also was designed for concomitant amplifica-was measured on a further aliquot by adding [13C2] oxalic
tion and sequencing of exons 6 and 7.acid as an internal standard and monitoring the same
Mutation screening was performed using PCR-basedfragment ions. Corrections were applied to account for
single-strand conformational polymorphism (SSCP) an-the levels of [13C2] oxalate present from the oral dose.
alysis as previously described [39, 40]. Automated SangerThe total amount of [13C2] oxalic acid (mg) excreted
dideoxy sequencing of the products (both reverse andover the six-hour interval after ingestion of the isotope
was calculated from the measured concentrations and forward directions) was completed using an ABI-3100
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Table 2. Clinical features at presentation
Patient/
Gender Age Symptoms Number of stones Medications Stone type
1 M 4 mos Fever, UTI Multiple small bilateral stones, None 100% COD
L-UVJ stone (1)
2 M 24 mos Penile & suprapubic pain, L-kidney (1), bladder stone (1) None Core: 80% COM,
microscopic hematuria 20% CaP
Shell: 70% COM,
30% COD
3 F 10 mos UTI, microscopic hematuria R-kidney (3), R-ureter (2), None 45% COM, 40%
L-kidney (3) COD, 15% CaP
4 M 5 yrs 5 mos Pain, inability to void R-kidney (3), L-kidney (1), Iron supplement 100% COM
distal urethral stone (1)
5 M 8 mos Gross hematuria Multiple small bilateral None 100% COD
parenchymal calcifications,
R-proximal ureteral stone (1)
6 M 4 mos Asymptomatic, family screening R-kidney (1) None 100% COM
Sequencer. When appropriate, sequence changes were (patients 5 and 6), and both parents of patient 4. A
history of urolithiasis in more distant relatives was foundconfirmed by restriction endonuclease digestion.
in all five of the families. A family history of renal failure
was not present in any family.
RESULTS The laboratory features at presentation are summa-
The clinical features of the six children at presentation rized in Table 3. Urine oxalate was 1.3 0.5 (1.3) mmol/
are summarized in Table 2. The mean age was 19.2 1.73 m2/24 h, mean SD (median), plasma oxalate 2.0
months (range 4 months to 5 5/12 years). Four of the six 0.3 (2.0) mol/L, serum creatinine 0.5 0.1 (0.5) mg/dL,
children were younger than 12 months of age at the time and 24-hour creatinine clearance was 90  19 (87) mL/
of initial clinical evaluation. Patient 4 was delivered at min/1.73 m2. Patient 3, with the lowest initial clearance,
35 weeks of gestation and weighed 2.25 kg. He required had left pyelocaliectasis and ureterectasis requiring pye-
a brief period of enteral tube feedings but not parenteral lolithotomy when first evaluated. After relief of the ob-
alimentation in the neonatal period. Neither hypercalci- struction, her creatinine clearance was 95 mL/min/1.73 m2.
uria nor nephrocalcinosis was detected in this child. The At presentation, urine glycolate was normal in four
other five children were delivered at term following un- children and mildly elevated in two (patients 1 and 3).
complicated pregnancies. Urine glycerate was normal in all. Subsequent determi-
In patient 1, ultrasound examination at presentation nations were normal in all children except patient 3. At
revealed bilateral renal duplication with increased echo- last follow-up at age 17 years, both her urine glycolate
genicity of the medullary pyramids on the right. The (246 g/mg creatinine) and l-glycerate (48 g/mg creati-
latter finding resolved by the age of 19 months. No in- nine) were elevated. Urine screened for organic acids
crease in medullary echogenicity was seen in the left was otherwise normal in all patients, as was urine for
kidney. A voiding cystourethrogram was normal in this amino acids. Hepatic AGT enzyme activity was normal
patient. In patient 5 a transient increase in echogenicity in the five children who underwent biopsy. Hepatic HPR
of the renal parenchyma, with a radiologic appearance activity was normal in four children and below normal
suggestive of early nephrocalcinosis, was observed on an in patient 2. Hepatic GR activity was normal in the four
excretory urogram at initial presentation but it resolved children in whom this assay was performed. This was
by the age of three years. Kidneys and urinary tracts of not measured in patient 2 due to unavailability of assay
the remaining four children were structurally normal by at the time of testing and insufficient amounts of tissue
ultrasound examination (N  2), intravenous pyelogra- available for later study.
phy (N  1), or computed tomography (N  1). Urine calcium was normal in four patients (2.2  0.56
With the exception of a very young infant in family 2, mg/kg/24 h, median 2.2) and elevated in two (patients 1
all parents and siblings were screened for hyperoxaluria and 5). Patient 1, who presented at the age of four
and hypercalciuria. Patients 5 and 6 are siblings. There months, had a calcium excretion rate of 9.5 mg/kg/24 h
are also two unaffected children in this family. Aside at initial evaluation. The hypercalciuria persisted and
from this affected sibling pair, no other first-degree rela- was 5.6 mg/kg/24 h at four years of age. His serum cal-
tives were found to have hyperoxaluria or are known to cium was normal throughout. In patient 5, at the time
have urolithiasis. Hypercalciuria was present in the fa- of presentation (8 months of age), his urine calcium/
creatinine ratio was 0.6 and the total serum calcium wasther of patient 1, both parents of the affected sibling pair
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10.9 mg/dL, with an ionized fraction of 5.5 mg/dL. Inter-
mittent hypercalciuria and normal serum calcium were
observed over time. When last evaluated, at age 14 years,
his total serum calcium was 9.7 mg/dL and urine calcium
was 1.2 mg/kg/24 h. PTH concentrations were normal
(2.3  0.3 pmol/L, median 2.4, N  4), as were serum
levels of calcitriol (40.4  20.4 pg/mL, median 47, N 5),
including both hypercalciuric children. Urine citrate was
1272 249 (median 1187, range 978 to 1622 mg/g creati-
nine). Values were normal for age in all children [41].
The study data are shown in Table 4. Dietary intakes
of oxalate and calcium were 42  31 (35) mg/day, and
779  398 (624) mg/day, respectively. None of the chil-
dren had clinical or laboratory evidence of malnutrition
and stool fat determinations were normal (1.3  1.7
g/day). Blood levels of pyridoxal 5-phosphate were nor-
mal in all children. At the time of the study, urine oxalate
was 1.5  0.5 (1.5) mmol/1.73 m2/24 h and iothalamate
clearance was 145 58 (123) mL/min/1.73 m2. Fractional
oxalate excretion was 4.2  1.4 (4.0). Recovery of [13C2]
oxalic acid in the urine after an oral load was used as a
marker of enteric oxalate absorption. The total recovery
during six hours following oral administration, expressed
as a percent of the total ingested load of [13C2] oxalic
acid, was 9.4  3.6% (8.0%), compared to 7.6  1.2%
(8.0%) in the six age-matched controls (P  0.33). No
correlation between % [13C2] oxalic acid recovery and
urine oxalate excretion rates was observed (r  0.13).
The renal handling of phosphate as determined by
TmPO4/GFR (mg/dL) was 4.5  1.0 (5.1) and within
age-specific normal ranges in the five children that were
tested. Additional parameters of renal tubular function
in these five children included the urine protein/osmolal-
ity ratio 0.07  0.06 (range 0.01 to 0.14), urine glucose
3.4  1.8 (range 1 to 5) mg/dL and FEUA 14.7  6.9
(range 7 to 24) %. No abnormalities were detected.
Patients were followed for 8.7  6.0 (9) years. Persis-
tent hyperoxaluria was observed in all children during
the 52 patient-years of follow-up (Fig. 2). Pyridoxine doses
of 5.4 2.6 (5.2) mg/kg/day had no effect on the oxalate
excretion rates of any of the children. Additional treat-
ment measures included neutral phosphates and oral
fluid hydration to maintain daily urinary volumes in ex-
cess of 0.75 liter in infants, 1.0 liter in preschoolers, 2.0
liters in school age children, and 2.5 liters in adolescents.
Adjunctive therapy with thiazides (patient 1) and/or ci-
trate (patients 1 and 4) was used when indicated. Four of
the patients spontaneously passed stones. Eight urologic
procedures for management of stones were required in
the six children. These included one open cystolithotomy,
one pyelolithotomy, two ultrasonic lithotripsies (percu-
taneous and ureteroscopic), one laser lithotripsy (ure-
teroscopic), two piezoelectric lithotripsies and one ure-
teroscopic stone extraction. The mean time from initial
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Table 4. Study data
EntericDietary Dietary
Age @ Dietary Urine Iothalamate Plasma oxalateoxalate calcium
study protein oxalate clearance oxalate absorption
Patient years mg/day g/kg/day mg/day mL/min/1.73 m2 lmol/L FEOx %
1 3.3 8a 451 3.6 48.4 248 3.1 4.9 4.9
2 5.3 51 426 2.3 57.2 104 2.3 4.2 14.3
3 15.6 23 1289 1.2 74.8 94 1.3 6.4 7.8
4 8.4 33 529 2.2 49.3 178 1.9 3.8 8.1
5 12.2 38 719 1.0 137.3 129 0.9 2.1 13.3
6 9.9 97 1263 2.8 135.5 116 2.0 3.8 7.9
a Patient 1 is on an oxalate restricted diet
Fig. 2. Urine oxalate (mmol/1.73 m2/24 h) in children with hyperoxal-
uria and urolithiasis. Moderate to marked hyperoxaluria persisted
throughout follow-up. The normal range is indicated by the shaded area.
was 10.3 months (range 0 to 29, median 5.5). Age at last
follow-up was 10.8  5.2 (11) years, with a measured
creatinine clearance of 107  14.8 (112) cc/min/1.73 m2.
Genetic analysis of the glycolate oxidase gene
Preliminary work with glycolate oxidase (GO) as the
candidate gene for a third type of inherited hyperoxal-
uria excluded deficiency of this enzyme as the cause of
hyperoxaluria in family 5. Analysis of family pedigrees
Fig. 3. (A) Family 5 pedigree. Family members with hyperoxaluria and
was consistent with an autosomal recessive pattern of urolithiasis are indicated by (). There were no family members with
hyperoxaluria alone or urolithiasis alone. (B) SSCP analysis (upperinheritance. Accordingly, we anticipated the affected sib-
panel) and Hae III endonuclease digestion (lower panel) of exon 5 GO.ship (patients 5 and 6) to share the same two mutant GO
Letters indicate the genotype at nucleotide 754. The PCR fragment
alleles, one inherited from each parent, both assumed size is 226 bp. The T754C change introduces a Hae III restriction site
at position 84. Numbers to the right indicate the lengths (bp) of theheterozygous carriers for the causative mutation. The
digested products.SSCP patterns and sequencing results of exon 5 in this
family, confirmed by Hae III endonuclease digestion, how-
ever, indicated the presence of different alleles in the
two affected brothers (Fig. 3). Patient 6 showed hetero-
zygosity for a synonymous T754C change (codon 252 in the remaining four patients (patients 1 to 4). Amplifi-
cation and sequencing of exon 4 revealed an IVS3 – 49TTG  CTG) while patient 5 was homozygous for the
wild-type sequence (TT). Thus, the pattern of inheri- CG change. This sequence change was homozygous in
patients 1 and 2 and heterozygous in patient 4. Patient 3tance of this T754C sequence variant effectively excluded
GO as the candidate gene in this family. was homozygous for the wild-type sequence (CC geno-
type), as was a control patient from University CollegeComprehensive screening by direct sequencing of all
GO exons and exon/intron boundaries was carried out London. No other sequence variation was identified by di-
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rect sequencing of the remaining exons and exon/intron without documented deficiency, may affect the net flux of
metabolites through the pathway, and is yet another po-boundaries of the GO gene in any patient.
tential mechanism for the hyperoxaluria in these children.
Organic acids and amino acids are involved in the
DISCUSSION
metabolic pathways leading to formation of oxalate. An
The distinctive clinical features of the children in this abnormality detected on urine screening for organic
report are the young age at stone development, with acids or amino acids would direct attention to the rele-
multiple calculi during infancy in four of six children, vant component of the metabolic pathway as a potential
and the persistent, moderate to marked hyperoxaluria cause of the hyperoxaluria. However, aside from the
of no identifiable primary or secondary cause. The find- hyperoxaluria, organic acid and amino acid screens were
ing of two affected siblings in one family suggests a ge- normal in our patients.
netic basis. We excluded known secondary causes of hyperoxal-
We excluded both known types of inherited hyper- uria. Plasma pyridoxal 5-phosphate concentrations were
oxalurias, PHI by normal levels of AGT, and PHII by normal in all of the patients. Dietary oxalate intake was
normal levels of GR and/or HPR and urinary l-glycerate. not excessive in any child and neither gastrointestinal dis-
Patients with PHII typically have markedly elevated uri- ease nor malabsorption was present. We further evalu-
nary l-glycerate [42], however, there is a recent report ated enteric oxalate absorption as a potential source of
of normal l-glycerate in two siblings with PHII [43]. The the hyperoxaluria by measuring [13C2] oxalate in the urine
possibility of type II primary hyperoxaluria remains in after ingestion of an oral load. There was no difference
patient 2 from our cohort, who had a mild reduction in (P  0.33) in % recovery of [13C2] oxalate between pa-
hepatic HPR activity and normal urine l-glycerate. The tients and age-matched controls.
unavailability of sufficient hepatic tissue and of the GR A potential role for the gastrointestinal tract in the
assay at the time of his screening precluded unequivocal degradation of dietary oxalate has emerged recently. Col-
exclusion of PH2. onization by several species of oxalate-degrading bacteria,
Mutation of glycolate oxidase could potentially con- including Oxalobacter formigenes [47] and lactic acid
tribute to hyperoxaluria either by increasing the affinity bacteria (L. acidophilus, S. thermophilus) [9], has been
of the enzyme for glyoxylate and thereby increasing shown to alter the oxalate excretion rates of some hyper-
intraperoxisomal oxalate production or, in deficiency oxaluric stone formers [9]. A decrease in the amount of
states, by conversion of its substrate glycolate to oxalate oxalate available for absorption within the colonic lumen
by as yet undefined pathways. Mutation screening of the as a result of the oxalate degrading ability of these bacte-
intron/exon boundaries and entire coding region of the ria is postulated to account for the observed reduction.
GO gene did not reveal any disease-associated sequence Effects of colonic bacteria on oxalate degradation may
changes in any of the five families. The two detected have been difficult to detect under the conditions of
sequence variants (T754C and IVS3-49 CG) are likely our oxalate absorption study. However, urine oxalate
polymorphisms. Nonetheless, many of the pathways par- excretion is often normal in the absence of oxalate de-
ticipating in hepatic metabolism of glyoxylate, and hence grading bacteria in the intestinal tract [47]. The absence
endogenous oxalate production, remain enigmatic [44] of oxalate degrading bacteria seems an unlikely mecha-
and the possibility of hepatic candidate enzymes other nism in our cohort of patients, as their urine oxalate
than GO accounting for the hyperoxaluria in this subset excretion rates were greater than the total dietary oxa-
of children remains to be explored. late intake by a mean factor of 2.0 and these rates were
Likewise, the net summation interaction of the known sustained in this range over many years.
various hepatic enzymes culminating in endogenous oxa- Hypercalciuria was a second risk factor for stone for-
late synthesis (AGT, GR/HPR, GO, LDH) has not been mation detected in two of the six children (patients 1
evaluated. Inborn errors of metabolism often show com- and 5). While we cannot conclusively exclude a common
plex phenotypes and partial defects of different enzymes renal tubulopathy accounting for the marked hyperoxal-
in a pathway may account for elusive clinical and bio- uria and hypercalciuria in the two hypercalciuric chil-
chemical findings, a concept termed ‘synergistic hetero- dren, the lack of linkage of the two traits in either family
zygosity’ [45]. This is particularly exemplified by patient 2 (families 1 and 5), the intermittent nature of the hyper-
whose AGT level was low normal and HPR activity calciuria in patient 5, and its absence despite hyperoxal-
was reduced. The combined effect of known molecular uria in this patient’s sibling, patient 6, suggests an inde-
variation, such as the C154T polymorphism of AGT [46], pendent cause for the abnormal calcium excretion.
and of other genes coding for enzymes in the glyoxylate Heightened renal tubular secretion of oxalate as the
pathway on cumulative hepatic oxalate production awaits sole explanation for the hyperoxaluria in these children
further investigation. For instance, ‘down-regulation’ of also does not seem likely given the degree of hyperoxal-
uria and the normal plasma oxalate concentrations ob-any one enzyme resulting from a given sequence change,
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served. Fractional excretion of oxalate in these children nism may not account for the findings in all patients
reported here. Confirmation of the source of hyperoxal-was similar to that observed in patients with primary
hyperoxaluria [22]. uria in these children awaits further study.
Renal oxalate synthesis is suggested by recent data
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